These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8488155)
1. Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Garde S; Sheth A; Porter AT; Pienta KJ Prostate; 1993; 22(3):225-33. PubMed ID: 8488155 [TBL] [Abstract][Full Text] [Related]
2. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Lokeshwar BL; Hurkadli KS; Sheth AR; Block NL Cancer Res; 1993 Oct; 53(20):4855-9. PubMed ID: 8402673 [TBL] [Abstract][Full Text] [Related]
3. A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. Garde SV; Sheth AR; Porter AT; Pienta KJ Cancer Lett; 1993 Jul; 70(3):159-66. PubMed ID: 7689036 [TBL] [Abstract][Full Text] [Related]
4. Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide. Sheth AR; Garde SV; Mehta MK; Shah MG Indian J Exp Biol; 1992 Mar; 30(3):157-61. PubMed ID: 1380948 [TBL] [Abstract][Full Text] [Related]
5. Similarities in the modulation of pituitary and prostatic FSH by inhibin and related peptides. Shah MG; Sheth AR Prostate; 1991; 18(1):1-8. PubMed ID: 1898990 [TBL] [Abstract][Full Text] [Related]
6. Regulation of inhibin subunit messenger ribonucleic acid levels by gonadotropins, growth factors, and gonadotropin-releasing hormone in cultured rat granulosa cells. LaPolt PS; Piquette GN; Soto D; Sincich C; Hsueh AJ Endocrinology; 1990 Aug; 127(2):823-31. PubMed ID: 2115434 [TBL] [Abstract][Full Text] [Related]
7. Postnatal treatment of human seminal plasma inhibin: gonadotropin and prolactin levels during the onset of puberty in the rat. Babu GN; Vijayan E Exp Clin Endocrinol; 1983 Nov; 82(3):342-6. PubMed ID: 6418556 [TBL] [Abstract][Full Text] [Related]
8. Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines. Fuerst J; Fiebiger E; Jungwirth A; Mack D; Talwar PG; Frick J; Rovan E Prostate; 1997 Jul; 32(2):77-84. PubMed ID: 9215394 [TBL] [Abstract][Full Text] [Related]
9. Decreased immunoexpression of prostate inhibin peptide in prostatic carcinoma: a study with monoclonal antibody. Zhang PJ; Driscoll DL; Lee HK; Nolan C; Velagapudi SR Hum Pathol; 1999 Feb; 30(2):168-72. PubMed ID: 10029444 [TBL] [Abstract][Full Text] [Related]
10. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model. Redding TW; Schally AV Prostate; 1985; 6(3):219-32. PubMed ID: 3157927 [TBL] [Abstract][Full Text] [Related]
11. Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer. Eldar-Geva T; Liberty G; Chertin B; Fridmans A; Farkas A; Margalioth EJ; Spitz IM Eur J Endocrinol; 2010 Jan; 162(1):177-81. PubMed ID: 19820037 [TBL] [Abstract][Full Text] [Related]
12. Studies on the carboxyl terminal peptides of human seminal plasma inhibin (HSPI). Chemical synthesis and in vivo biological activity of the disulfide loop peptide 67-94 of HSPI. Mahale SD; Sheth AR; Iyer KS Int J Pept Protein Res; 1993 Aug; 42(2):132-7. PubMed ID: 8407107 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of prolactin on rat dorsolateral prostate and R3327 prostatic tumor sublines. Johnson MP; Thompson SA; Lubaroff DM J Urol; 1985 Jun; 133(6):1112-20. PubMed ID: 4039764 [TBL] [Abstract][Full Text] [Related]
14. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer. Naik HR; Lehr JE; Pienta KJ Anticancer Res; 1994; 14(6B):2617-9. PubMed ID: 7872690 [TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion. Ip MM; Sylvester PW; Schenkel L Cancer Res; 1986 Apr; 46(4 Pt 1):1735-40. PubMed ID: 3948162 [TBL] [Abstract][Full Text] [Related]
16. Inhibin-mediated feedback control of follicle-stimulating hormone secretion in the female rat. Rivier C; Rivier J; Vale W Science; 1986 Oct; 234(4773):205-8. PubMed ID: 3092356 [TBL] [Abstract][Full Text] [Related]
17. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741 [TBL] [Abstract][Full Text] [Related]
18. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV Prostate; 1992; 20(4):297-310. PubMed ID: 1351672 [TBL] [Abstract][Full Text] [Related]
19. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma. Sylvester PW; Ip MM Prostate; 1987; 10(1):57-67. PubMed ID: 3822918 [TBL] [Abstract][Full Text] [Related]
20. Detection of prostatic-inhibin-like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell line. Hurkadli KS; Lokeshwar B; Sheth AR; Block NL Prostate; 1994 Jun; 24(6):285-90. PubMed ID: 8208622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]